Patterns of corticosteroid use among remdesivir and matched patients and associated clinical outcomes in hospitalized COVID-19 patients

被引:0
|
作者
Papic, Ivan [1 ]
Bistrovic, Petra [2 ]
Keres, Tatjana [3 ]
Hadziabdic, Maja Ortner [4 ]
Lucijanic, Marko [5 ,6 ,7 ]
机构
[1] Univ Hosp Dubrava, Pharm Dept, Zagreb, Croatia
[2] Univ Hosp Dubrava, Cardiol Dept, Zagreb, Croatia
[3] Univ Hosp Dubrava, Intens Care Dept, Zagreb, Croatia
[4] Univ Zagreb, Fac Pharm & Biochem, Ctr Appl Pharm, Zagreb, Croatia
[5] Univ Hosp Dubrava, Hematol Dept, Av Gojka Suska 6, Zagreb, Croatia
[6] Univ Zagreb, Sch Med, Internal Med Dept, Zagreb, Croatia
[7] Univ Zagreb, Sch Med, Zagreb 10000, Croatia
关键词
Remdesivir; corticosteroids; prognosis; dexamethasone; methylprednisolone; prednisone;
D O I
10.1080/14656566.2024.2320255
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
IntroductionWe aimed to investigate patterns of corticosteroid use and their relationship with remdesivir use and clinical outcomes in a large real-life cohort of COVID-19 patients treated in a tertiary-level institution.MethodsWe retrospectively analyzed a total of 1558 severe and critical COVID-19 patients, including 779 patients treated with remdesivir and 779 matched control patients.ResultsA total of 167 (10.7%) patients received none, 710 (45.6%) low, 539 (34.6%) high, and 142 (9.1%) very high corticosteroid doses. Patients treated with remdesivir had significantly longer exposure to corticosteroids, received higher average and maximal daily doses, and cumulative corticosteroid doses. In the multivariate analysis remdesivir use, lower cumulative comorbidity burden, higher severity of COVID-19 symptoms, and mechanical ventilation were recognized as mutually independent predictors of the use of higher corticosteroid doses. Higher corticosteroid doses were associated with significantly increased mortality.Among non-remdesivir treated patients, there was a U-shaped relationship between maximal daily corticosteroid dose and mortality. Among remdesivir treated patients gradual increase in mortality with increasing corticosteroid doses was observed.ResultsA total of 167 (10.7%) patients received none, 710 (45.6%) low, 539 (34.6%) high, and 142 (9.1%) very high corticosteroid doses. Patients treated with remdesivir had significantly longer exposure to corticosteroids, received higher average and maximal daily doses, and cumulative corticosteroid doses. In the multivariate analysis remdesivir use, lower cumulative comorbidity burden, higher severity of COVID-19 symptoms, and mechanical ventilation were recognized as mutually independent predictors of the use of higher corticosteroid doses. Higher corticosteroid doses were associated with significantly increased mortality.Among non-remdesivir treated patients, there was a U-shaped relationship between maximal daily corticosteroid dose and mortality. Among remdesivir treated patients gradual increase in mortality with increasing corticosteroid doses was observed.ConclusionPatterns of corticosteroid use differ regarding the use of remdesivir and may moderate its association with survival among severe and critical COVID-19 patients.
引用
收藏
页码:215 / 222
页数:8
相关论文
共 50 条
  • [1] Early Use of Remdesivir in Patients Hospitalized With COVID-19 Improves Clinical Outcomes A Retrospective Observational Study
    Paranjape, Neha
    Husain, Mir
    Priestley, Jennifer
    Koonjah, Yashila
    Watts, Christopher
    Havlik, Joseph
    INFECTIOUS DISEASES IN CLINICAL PRACTICE, 2021, 29 (05) : E282 - E286
  • [2] Comparison of safety and outcomes related to remdesivir treatment among dialysis patients hospitalized with COVID-19
    Zaki, Kirollos E.
    Huang, Cheng-Wei
    Zhou, Hui
    Chung, Joanie
    Selevan, David C.
    Rutkowski, Mark P.
    Sim, John J.
    CLINICAL KIDNEY JOURNAL, 2022, 15 (11) : 2056 - 2062
  • [3] Real-life use of remdesivir in hospitalized patients with COVID-19
    Garcia-Vidal, Carolina
    Meira, Fernanda
    Duenas, Gerard
    Puerta-Alcalde, Pedro
    Garcia-Pouton, Nicole
    Chumbita, Mariana
    Cardozo, Celia
    Hernandez-Meneses, Marta
    Alonso-Navarro, Rodrigo
    Rico, Veronica
    Aguero, Daiana
    Bodro, Marta
    Morata, Laura
    Jordan, Carlota
    Lopera, Carlos
    Ambrosioni, Juan
    Segui, Ferran
    Grafia, Nacho
    Castro, Pedro
    Garcia, Felipe
    Mensa, Josep
    Martinez, Jose Antonio
    Sanjuan, Gemma
    Soriano, Alex
    Cozar-Llisto, Alberto
    REVISTA ESPANOLA DE QUIMIOTERAPIA, 2021, 34 (02) : 136 - 140
  • [4] Outcomes Among Patients Hospitalized for COVID-19 Treated with Remdesivir in an Urban Center Pre-COVID-19 Vaccination
    Chew, Debra
    Shiau, Stephanie
    Sudharshan, Sree
    Alankar, Aparna
    Desilva, Malithi
    Kodali, Swetha
    Raquepo, Tricia Mae
    Meilad, Naema
    Sudyn, Alexander
    Swaminathan, Shobha
    JOURNAL OF RACIAL AND ETHNIC HEALTH DISPARITIES, 2025, 12 (01) : 173 - 180
  • [5] Remdesivir plus dexamethasone is associated to improvement in the clinical outcome of COVID-19 hospitalized patients regardless of their vaccination status
    Bernal, Enrique
    Garcia-Villalba, Eva
    Pons, Eduardo
    Hernandez, Maria Dolores
    Baguena, Carlos
    Puche, Gabriel
    Carter, Paula
    Martinez, Monica
    Alcaraz, Antonia
    Tomas, Cristina
    Munoz, Angeles
    Vicente, Maria Rosario
    Nunez, Maria Luz
    Sancho, Natalia
    Villalba, Mari Carmen
    Cano, Alfredo
    Minguela, Alfredo
    MEDICINA CLINICA, 2023, 161 (04): : 139 - 146
  • [6] Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes
    van Paassen, Judith
    Vos, Jeroen S.
    Hoekstra, Eva M.
    Neumann, Katinka M. I.
    Boot, Pauline C.
    Arbous, Sesmu M.
    CRITICAL CARE, 2020, 24 (01)
  • [7] Remdesivir in treating hospitalized patients with COVID-19: A renewed review of clinical trials
    Wu, Zhenchao
    Han, Zhifei
    Liu, Beibei
    Shen, Ning
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [8] Clinical outcomes of hospitalized COVID-19 patients treated with remdesivir: a retrospective analysis of a large tertiary care center in Germany
    Kathrin Marx
    Ksenija Gončarova
    Dieter Fedders
    Sven Kalbitz
    Nils Kellner
    Maike Fedders
    Christoph Lübbert
    Infection, 2023, 51 : 97 - 108
  • [9] Clinical outcomes of hospitalized COVID-19 patients treated with remdesivir: a retrospective analysis of a large tertiary care center in Germany
    Marx, Kathrin
    Goncarova, Ksenija
    Fedders, Dieter
    Kalbitz, Sven
    Kellner, Nils
    Fedders, Maike
    Luebbert, Christoph
    INFECTION, 2023, 51 (01) : 97 - 108
  • [10] The Cost-Effectiveness of Remdesivir for Hospitalized Patients With COVID-19
    Whittington, Melanie D.
    Pearson, Steven D.
    Rind, David M.
    Campbell, Jonathan D.
    VALUE IN HEALTH, 2022, 25 (05) : 744 - 750